Assignee
BIOLOGICAL E LTD
IN·16 granted patents·7 pending applications·6 citations·filing 2015–2024
Top patents by PatentIndex Score
23 records- 0182US12465632B2Purified capsular polysaccharides of Streptococcus pneumoniaeBIOLOGICAL E LTD·Filed 2024·Granted Nov 11, 2025·0 cites·11 claims
- 0278US11147863B2Multivalent pneumococcal conjugate vaccineBIOLOGICAL E LTD·Filed 2016·Granted Oct 19, 2021·2 cites·4 claims
- 0373US11547752B2Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugatesBIOLOGICAL E LTD·Filed 2019·Granted Jan 10, 2023·1 cites·16 claims
- 0473US10836839B2Method for separation of protein and other impurities from microbial capsular polysaccharidesBIOLOGICAL E LTD·Filed 2016·Granted Nov 17, 2020·2 cites·12 claims
- 0571US12048739B2Purified capsular polysaccharides of Streptococcus pneumoniaeBIOLOGICAL E LTD·Filed 2019·Granted Jul 30, 2024·0 cites·12 claims
- 0671US10280409B2Codon optimized polynucleotide for high level expression of CRM197BIOLOGICAL E LTD·Filed 2015·Granted May 7, 2019·1 cites·14 claims
- 0764US2023322871A1Expression of pneumococcal surface protein a (pspa)BIOLOGICAL E LTD·Filed 2023·Application pending·0 cites
- 0863US12276645B2Methods for quantification of carbohydratesBIOLOGICAL E LTD·Filed 2020·Granted Apr 15, 2025·0 cites·10 claims
- 0963US11680111B2Method for separation of protein and other impurities from microbial capsular polysaccharidesBIOLOGICAL E LTD·Filed 2020·Granted Jun 20, 2023·0 cites·5 claims
- 1061US12318437B2Vaccine formulations comprising preservativeBIOLOGICAL E LTD·Filed 2019·Granted Jun 3, 2025·0 cites·10 claims
- 1158US2025059550A1Constructs and methods for increased expression of polypeptidesBIOLOGICAL E LTD·Filed 2022·Application pending·0 cites
- 1256US11725029B2Expression of pneumococcal surface protein a (PSPA)BIOLOGICAL E LTD·Filed 2019·Granted Aug 15, 2023·0 cites·14 claims
- 1355US11420993B2Semi-synthetic meningococcal conjugate vaccineBIOLOGICAL E LTD·Filed 2019·Granted Aug 23, 2022·0 cites·7 claims
- 1453US2023002468A1N-terminal extension sequence for expression of recombinant therapeutic peptidesBIOLOGICAL E LTD·Filed 2020·Application pending·0 cites
- 1552US2023101892A1Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugatesBIOLOGICAL E LTD·Filed 2022·Application pending·0 cites
- 1651US2024230545A9Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine compositionBIOLOGICAL E LTD·Filed 2022·Application pending·0 cites
- 1749US11098089B2Method for high level production of CRM197BIOLOGICAL E LTD·Filed 2018·Granted Aug 24, 2021·0 cites·18 claims
- 1847US2022143166A1Multivalent pneumococcal polysaccharide-protein conjugate vaccineBIOLOGICAL E LTD·Filed 2019·Application pending·0 cites
- 1946US11492421B2Process for the preparation of Dalteparin sodiumBIOLOGICAL E LTD·Filed 2019·Granted Nov 8, 2022·0 cites·11 claims
- 2040US11299558B2Process for the preparation of low molecular weight heparinBIOLOGICAL E LTD·Filed 2018·Granted Apr 12, 2022·0 cites·13 claims
- 2138US10744200B2Method for preparation of aluminium phosphate gel for application in vaccine formulationsBIOLOGICAL E LTD·Filed 2016·Granted Aug 18, 2020·0 cites·11 claims
- 2233US2017198004A1Novel semi-synthetic meningococcal conjugate vaccineBIOLOGICAL E LTD·Filed 2015·Application pending·0 cites
- 2332US10927149B2Industrially scalable process for recovering biologically active recombinant carrier proteinsBIOLOGICAL E LTD·Filed 2016·Granted Feb 23, 2021·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when BIOLOGICAL E LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →